# NSD2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The NSD2 gene encodes a histone H3 lysine 36 (H3K36) mono- and di-methyltransferase, acting as a critical epigenetic regulator. Dysregulation through translocation (e.g., t(4;14) in multiple myeloma), activating point mutations (e.g., E1099K in pediatric ALL), or overexpression drives multiple malignancies.
- Germline loss-of-function variants in NSD2 cause Rauch–Steindl syndrome (RAUST), a neurodevelopmental disorder, highlighting its essential role in human development. The gene's locus at 4p16.3 is also implicated in Wolf–Hirschhorn syndrome.
- NSD2 possesses distinct functional domains, including PWWP domains for H3K36me2/me3 binding and multiple PHD fingers for H3K4me0 binding, which mediate its recruitment to chromatin and influence transcriptional programs. Structural studies reveal the SET domain's catalytic mechanism and the impact of mutations like E1099K on substrate specificity.
- In multiple myeloma, the t(4;14) translocation leads to NSD2 overexpression, causing global H3K36me2 increase, epigenetic reprogramming, and activation of oncogenes like CCND1 and PTP4A3. This contributes to aggressive disease and poor prognosis.
- NSD2 is a validated therapeutic target, with small-molecule inhibitors like KTX-1001 in clinical trials for relapsed/refractory multiple myeloma. Targeted protein degraders (PROTACs) are also being developed to eliminate NSD2 protein.
- The E1099K activating mutation in NSD2 is a significant driver of glucocorticoid resistance in pediatric ALL by disrupting glucocorticoid receptor signaling and pro-apoptotic factor expression.

---

## Executive Summary & Key Metadata

The **NSD2** gene (Nuclear Receptor Binding SET Domain Protein 2), also known as **WHSC1** (Wolf-Hirschhorn Syndrome Candidate 1) and **MMSET** (Multiple Myeloma SET Domain-Containing Protein), encodes a histone lysine methyltransferase (KMT) that primarily catalyzes the mono- and di-methylation of histone H3 at lysine 36 (H3K36me1/me2) [1, 2, 3]. NSD2 is a master epigenetic regulator whose dysregulation—via chromosomal translocation, activating point mutation, or overexpression—is a driver event in multiple malignancies, most notably multiple myeloma (MM), acute lymphoblastic leukemia (ALL), and mantle cell lymphoma (MCL) [2, 4, 5, 6]. Conversely, germline loss-of-function variants in NSD2 cause Rauch–Steindl syndrome (RAUST), a rare neurodevelopmental disorder related to Wolf–Hirschhorn syndrome (WHS) [1, 2, 7].

| **Attribute** | **Detail** |
|---|---|
| HGNC Symbol | NSD2 (alias: WHSC1, MMSET, KMT3G) |
| UniProt Accession | O96028 |
| Representative PDB ID | 6L4Q (cryo-EM structure of NSD2 bound to nucleosome) [3] |
| Chromosomal Locus | 4p16.3 |
| Primary Molecular Function | Histone H3 lysine 36 (H3K36) mono- and di-methyltransferase |
| Disease & Pathology Associations | t(4;14) Multiple Myeloma; Pediatric ALL (E1099K); Mantle Cell Lymphoma; Rauch–Steindl Syndrome; Wolf–Hirschhorn Syndrome; Prostate, Lung, Colorectal, Breast, and Head & Neck Cancers |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Location and Genomic Architecture

The NSD2 gene is located on the short arm of chromosome 4 at band p16.3 (4p16.3), a region historically defined as the Wolf–Hirschhorn syndrome critical region (WHSCR) [4, 5, 7]. The gene spans approximately 90 kilobases of genomic DNA on the minus strand (NCBI GRCh38: chr4:1,878,406–1,968,561). The locus is gene-dense and shares its chromosomal neighborhood with several other developmentally critical genes, including *LETM1*, *WHSC1L1* (NSD3), and *FGFR3* [4]. The proximity of NSD2 to the immunoglobulin heavy chain (IGH) locus on chromosome 14q32 sets the stage for the recurrent t(4;14)(p16;q32) translocation in MM [2, 4, 6].

### 1.2 Promoter Architecture and Regulatory Elements

The NSD2 promoter region lacks a canonical TATA box but contains multiple GC-rich Sp1-binding sites, consistent with its broad, low-level expression in most tissues. The promoter is embedded within a CpG island that spans the first exon and extends into intron 1. In t(4;14) MM, the translocation juxtaposes the IGH enhancers (Eμ and 3'α enhancers) downstream or upstream of NSD2, leading to a dramatic overexpression of the gene—often 10- to 100-fold above normal plasma cell levels [2, 4, 7]. The translocation breakpoints are heterogeneous; approximately 60% occur in the 5' region of NSD2 (between exons 1–3), while 40% occur in the 3' region (introns 9–24) [6]. Critically, the location of the breakpoint correlates with clinical outcome: patients with breakpoints in the 5' region (resulting in expression of full-length NSD2 isoforms) have a significantly worse prognosis than those with 3' breakpoints (which produce N-terminally truncated isoforms) [6].

### 1.3 Transcription Factor Binding and Enhancer Elements

Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project reveal that the NSD2 promoter is bound by a constellation of transcription factors, including MYC, MAX, E2F1, and FOXA1 [1]. In prostate cancer, NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome complex, where it is recruited to androgen receptor-bound enhancer elements to deposit H3K36me2 and facilitate transcriptional activation of AR target genes [1]. In t(4;14) MM, the IGH enhancers act as super-enhancers that drive NSD2 overexpression, and the resulting high levels of NSD2 protein further remodel the enhancer landscape by depositing H3K36me2 at active enhancers and gene bodies [2, 3].

### 1.4 Alternative Splicing and Isoforms

The NSD2 gene undergoes extensive alternative splicing, producing at least four major protein isoforms:

| **Isoform** | **Size (aa)** | **Molecular Weight (kDa)** | **Key Domains** | **Expression Context** |
|---|---|---|---|---|
| MMSET I (Full-length) | 1365 | ~152 | PWWP, PHD, SET, AWS, Post-SET | Ubiquitous, low-level |
| MMSET II (Full-length) | 1365 | ~152 | PWWP, PHD, SET, AWS, Post-SET | t(4;14) MM, overexpressed |
| RE-IIBP (Short isoform) | 647 | ~73 | PWWP, PHD, SET (partial) | Testis, some cancers |
| MMSET III (Truncated) | 584 | ~66 | PWWP, PHD (partial) | t(4;14) MM with 3' breakpoints |

The full-length isoforms (MMSET I and II) differ only in their 5' untranslated regions (UTRs) and encode identical proteins [4]. The RE-IIBP isoform arises from an internal promoter in intron 12 and retains the SET domain but lacks the N-terminal PWWP and PHD domains [4]. In t(4;14) MM with 3' breakpoints, the translocation produces N-terminally truncated NSD2 proteins that retain the catalytic SET domain but lack the chromatin-reading PWWP and PHD domains [5, 6]. These truncated isoforms have altered substrate specificity and chromatin localization, contributing to the distinct clinical phenotype of this patient subgroup [5, 6].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The NSD2 protein (UniProt O96028) is a 1365-amino-acid polypeptide with a modular architecture comprising multiple chromatin-binding and catalytic domains. From N-terminus to C-terminus, the domain organization is as follows:

| **Domain** | **Residues (approx.)** | **Function** |
|---|---|---|
| PWWP domain 1 | 260–330 | Binds H3K36me2/me3; nucleolar localization |
| PWWP domain 2 | 550–620 | Binds H3K36me2; DNA binding |
| PHD finger 1 | 700–750 | Binds H3K4me0; transcriptional regulation |
| PHD finger 2 | 760–810 | Binds H3K4me0; transcriptional regulation |
| PHD finger 3 | 820–870 | Binds H3K4me0; transcriptional regulation |
| PHD finger 4 | 880–930 | Binds H3K4me0; transcriptional regulation |
| PHD finger 5 | 940–990 | Binds H3K4me0; transcriptional regulation |
| AWS domain | 1000–1050 | Structural support for SET domain |
| SET domain | 1050–1200 | Catalytic methyltransferase activity |
| Post-SET domain | 1200–1230 | Zinc coordination; substrate specificity |

The catalytic SET domain (residues ~1050–1200) is the defining feature of the protein and is responsible for the transfer of methyl groups from S-adenosyl-L-methionine (SAM) to the ε-amino group of H3K36 [3]. The SET domain is flanked by an AWS (Associated With SET) domain and a Post-SET domain, both of which contain zinc-binding motifs that stabilize the catalytic core [3].

### 2.2 Structural Biology of the SET Domain

The cryo-electron microscopy (cryo-EM) structure of NSD2 bound to a nucleosome (PDB: 6L4Q) was solved at 3.2 Å resolution and revealed the molecular basis of NSD2 substrate recognition [3]. The SET domain adopts a canonical SET-domain fold consisting of a β-sheet-rich core flanked by α-helices. The SAM cofactor binds in a deep pocket formed by the SET and Post-SET domains, while the H3K36 side chain inserts into a narrow substrate channel [3].

Key structural features of the NSD2 SET domain:

- **The SET-I domain** (residues ~1050–1100) forms a "pseudo-knot" structure that is essential for catalytic activity. The E1099 residue, which is mutated to lysine (E1099K) in pediatric ALL, lies within this region and is critical for substrate specificity [3, 6].
- **The Post-SET domain** contains a zinc-binding CCCC motif that coordinates a zinc ion, stabilizing the active site architecture. Mutations in this region (e.g., T1150A) alter the enzyme's processivity and can introduce H3K36 trimethylation activity [6].
- **The AWS domain** forms a "molecular ruler" that positions the target lysine correctly within the active site. The AWS domain also mediates interactions with the nucleosome acidic patch, which is required for efficient catalysis [3].

### 2.3 Chromatin-Reading Domains

The two PWWP domains are members of the "Royal family" of methyl-lysine binding domains. PWWP1 (residues 260–330) binds H3K36me2/me3 with micromolar affinity and is required for NSD2's nucleolar localization [1, 7]. PWWP2 (residues 550–620) also binds H3K36me2 and contributes to chromatin association. A chemical probe targeting the PWWP domain (compound UNC6934) was shown to displace NSD2 from the nucleolus, demonstrating the functional importance of these domains for NSD2 subnuclear localization [1, 7].

The five PHD fingers are arranged in a tandem array and bind unmodified H3K4 (H3K4me0). This binding specificity allows NSD2 to be recruited to genomic loci that lack H3K4 methylation, such as intergenic regions and enhancers [2, 3]. The PHD fingers are essential for NSD2's oncogenic function in MM: deletion of the PHD domain abrogates NSD2's ability to drive tumorigenesis in xenograft models [2, 3].

### 2.4 Post-Translational Modifications

NSD2 is subject to multiple post-translational modifications that regulate its activity:

- **PARylation**: PARP1 poly(ADP-ribosyl)ates NSD2 at multiple sites, which reduces its histone methyltransferase activity and impedes chromatin binding [4].
- **Phosphorylation**: NSD2 is phosphorylated by PKCα at serine 172, which promotes its nuclear export and cytoplasmic functions in metabolic reprogramming [5].
- **Ubiquitination**: NSD2 is targeted for proteasomal degradation by the E3 ubiquitin ligase SIAH2, providing a mechanism for rapid turnover [5].

### 2.5 Interactive 3D Visualizer

> **🔬 Interactive 3D Protein Visualizer: Load NSD2 (PDB: 6L4Q)**
>
> [**Launch the Interactive 3D Protein Visualizer**](/tools/protein-structure-viewer?source=alphafold&accession=O96028)
>
> This tool allows you to explore the cryo-EM structure of NSD2 bound to the nucleosome (PDB: 6L4Q). Key features to examine:
> - **SET domain** (residues 1050–1200): The catalytic core, colored in red.
> - **E1099 residue**: The mutational hotspot in pediatric ALL, shown as spheres.
> - **PWWP domains**: The H3K36me2 reader modules, colored in blue.
> - **PHD fingers**: The H3K4me0 reader modules, colored in green.
> - **Nucleosome**: The H3K36 substrate lysine is highlighted in yellow.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Histone Methyltransferase Activity

NSD2 is the primary enzyme responsible for the dimethylation of H3K36 (H3K36me2) in mammalian cells [1, 2, 3]. H3K36me2 is a histone mark associated with active transcription, deposited across gene bodies and intergenic regions. NSD2 also catalyzes H3K36me1, but has negligible activity for H3K36me3 under normal conditions [3]. The enzyme requires the presence of the nucleosome for efficient catalysis; free histones are poor substrates [3, 6].

The H3K36me2 mark deposited by NSD2 serves multiple functions:

- **Transcriptional elongation**: H3K36me2 is enriched in the gene bodies of actively transcribed genes and is recognized by the histone chaperone SPT6, which facilitates transcription elongation [7].
- **DNA methylation maintenance**: H3K36me2 recruits DNMT3A/B to intergenic regions, maintaining DNA methylation at these loci [2, 4].
- **Splicing regulation**: H3K36me2 influences alternative splicing by recruiting splicing factors such as PTB and SRSF1.
- **Chromatin structure**: H3K36me2 antagonizes the deposition of H3K27me3 by PRC2, thereby preventing Polycomb-mediated repression [1, 2].

### 3.2 The t(4;14) Translocation and Oncogenic Signaling in Multiple Myeloma

The t(4;14)(p16;q32) translocation is present in approximately 12–20% of MM cases and results in the overexpression of NSD2 under the control of IGH enhancers [2, 4, 6]. NSD2 overexpression leads to a dramatic increase in global H3K36me2 levels, which drives a specific oncogenic transcriptional program [2, 3].

The molecular mechanisms by which NSD2 drives MM pathogenesis include:

1. **Epigenomic reprogramming**: NSD2 overexpression remodels the chromatin landscape, increasing H3K36me2 at gene bodies and enhancers while decreasing H3K27me3 at Polycomb target genes [2, 3]. This leads to the activation of oncogenes and the repression of tumor suppressors.

2. **Transcriptional activation of oncogenes**: NSD2 directly regulates the expression of key oncogenes in MM, including *CCND1* (cyclin D1), *PTP4A3* (PRL-3), and *TWIST1* [3, 4, 5, 6]. The PHD domain of NSD2 is required for its recruitment to these oncogenic loci [2, 3].

3. **NF-κB activation**: NSD2 mediates constitutive NF-κB signaling through a feed-forward loop involving the activation of NF-κB target genes, which promotes MM cell proliferation and survival [7].

4. **Metabolic reprogramming**: NSD2 activates PKCα, which drives metabolic reprogramming through the pentose phosphate pathway, promoting lenalidomide resistance [1, 5].

5. **Immune evasion**: NSD2 modulates immune surveillance in MM by regulating the expression of immune checkpoint ligands and antigen presentation machinery [2].

### 3.3 NSD2 in B-Cell Development and Lymphocyte Differentiation

NSD2 plays essential roles in B-cell development. Conditional knockout of NSD2 in mice reveals that the catalytic SET domain is required for the generation of B1 cells, a subset of innate-like B cells that produce natural antibodies [3, 4]. NSD2 also links developmental plasticity to mitochondrial function in muscle and lymphocyte differentiation, suggesting a broader role in cellular metabolism and differentiation [5].

### 3.4 NSD2 in Solid Tumors

Beyond MM, NSD2 is overexpressed or mutated in a wide range of solid tumors:

- **Lung adenocarcinoma (LUAD)**: NSD2 cooperates with oncogenic KRAS signaling to drive LUAD pathogenesis. The hyperactive E1099K variant, when expressed in vivo, promotes tumor formation [6].
- **Colorectal cancer (CRC)**: NSD2 is overexpressed in CRC and promotes tumorigenesis through the activation of oncogenic transcriptional programs [1, 7].
- **Prostate cancer**: NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome complex and is required for androgen receptor-driven transcription [1]. NSD2 expression correlates with T-cell infiltration and prognosis in prostate cancer [1].
- **Osteosarcoma**: NSD2 regulates apoptosis and chemosensitivity in osteosarcoma cells [2].
- **Breast cancer**: NSD2 is differentially expressed in breast cancers and drives endocrine resistance through metabolic reprogramming [1, 3].

### 3.5 Protein-Protein Interaction Networks

NSD2 interacts with a diverse array of proteins that modulate its function:

| **Interactor** | **Function** | **Reference** |
|---|---|---|
| SMARCA2 (BRM) | Chromatin remodeling; co-regulation of oncogenes | [5, 6] |
| SPT6 | Transcription elongation; interferon-induced transcription | [7] |
| PARP1 | PARylation; inhibition of NSD2 activity | [4] |
| PKCα | Phosphorylation; metabolic reprogramming | [5] |
| ISWI complexes | Recruitment to pericentromeric heterochromatin | [4] |
| DNMT3A/B | DNA methylation maintenance | [2] |
| AR/FOXA1 | Prostate cancer enhanceosome | [1] |
| ZHX3 | Transcriptional repression; senescence | [5] |

### 3.6 Signaling Pathway Diagram

```mermaid
flowchart TD
    A["t("4;14") Translocation"] --> B["IGH Enhancers Drive NSD2 Overexpression"]
    B --> C["Global H3K36me2 Increase"]
    C --> D["Activation of Oncogenes: CCND1, PTP4A3, TWIST1"]
    C --> E["Repression of H3K27me3 at PRC2 Targets"]
    C --> F["DNA Methylation Changes via DNMT3A/B"]
    D --> G["MM Cell Proliferation & Survival"]
    E --> G
    F --> G
    G --> H["Clinical Manifestation: High-Risk MM"]
    
    I["NSD2 E1099K Mutation"] --> J["Increased H3K36me2/me3"]
    J --> K["Altered 3D Chromatin Organization"]
    K --> L["Glucocorticoid Resistance in ALL"]
    L --> M["Relapsed Pediatric ALL"]
    
    N["NSD2 Loss-of-Function"] --> O["Reduced H3K36me2"]
    O --> P["Abnormal Development: RAUST/WHS"]
    O --> Q["Senescence-Associated Epigenomic Remodeling"]
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Activating Mutations in Cancer

#### 4.1.1 E1099K (p.Glu1099Lys)

The E1099K mutation is the most well-characterized activating mutation in NSD2. It is found in approximately 5–10% of pediatric ALL cases, particularly at relapse, and is also present in MCL and LUAD [1, 2, 5, 6, 7]. The mutation is located in the SET-I domain and alters the substrate specificity of the enzyme, allowing it to catalyze H3K36me3 in addition to H3K36me2 [6].

Functional consequences of E1099K:

- **Increased catalytic activity**: The mutation increases the enzyme's processivity and allows trimethylation of H3K36 [6].
- **Altered chromatin organization**: E1099K disrupts 3D chromatin architecture, leading to changes in topologically associating domains (TADs) and enhancer-promoter interactions [3, 4].
- **Glucocorticoid resistance**: E1099K drives glucocorticoid resistance in ALL by blocking glucocorticoid receptor auto-induction and the expression of pro-apoptotic factors BIM and BMF [1, 2, 7].
- **Oncogenic reprogramming**: The mutation drives a specific gene expression program that promotes cell proliferation, migration, and invasion [5, 6].

#### 4.1.2 T1150A (p.Thr1150Ala)

The T1150A mutation is a cancer-associated variant that also introduces H3K36 trimethylation activity [6]. This mutation is found in a subset of solid tumors and is thought to act similarly to E1099K by altering the substrate specificity of the SET domain.

#### 4.1.3 Other Cancer-Associated Mutations

Additional NSD2 mutations have been identified in various cancers, including:

- **E1099K** (ALL, MCL, LUAD) [5, 6]
- **T1150A** (solid tumors) [6]
- **Y1178C** (colorectal cancer) [6]
- **R1185Q** (colorectal cancer) [6]
- **P1103S** (mantle cell lymphoma) [5]

### 4.2 Loss-of-Function Mutations in Developmental Disorders

#### 4.2.1 Rauch–Steindl Syndrome (RAUST)

Germline loss-of-function variants in NSD2 cause Rauch–Steindl syndrome (RAUST, OMIM #617542), a rare autosomal dominant disorder characterized by [1, 2, 7]:

- Prenatal and postnatal growth retardation
- Distinctive facial dysmorphisms (prominent forehead, hypertelorism, broad nasal bridge)
- Variable developmental delay and intellectual disability
- Muscular hypotonia
- Feeding difficulties

The syndrome is caused by heterozygous truncating variants, missense variants, or multi-exon deletions in NSD2 [1, 2, 7]. Functional studies demonstrate that these variants result in decreased histone methyltransferase activity [2]. The clinical phenotype of RAUST is milder than that of Wolf–Hirschhorn syndrome, which is caused by contiguous gene deletions of 4p16.3 that include NSD2 and other genes [4, 5, 7].

#### 4.2.2 Wolf–Hirschhorn Syndrome (WHS)

WHS is a contiguous gene syndrome caused by heterozygous deletions of chromosome 4p16.3 [4, 5, 7]. The condition is characterized by:

- "Greek warrior helmet" facial appearance
- Severe growth retardation
- Intellectual disability
- Seizures
- Congenital heart defects

NSD2 is considered a critical gene for the WHS phenotype, and loss-of-function variants in NSD2 alone produce a DNA methylation signature similar to that seen in WHS [3, 4]. However, the full WHS phenotype requires the deletion of additional genes in the region, including *LETM1* and *FGFR3* [4, 7].

### 4.3 Clinical Differentials and Diagnostic Considerations

The differential diagnosis of NSD2-related disorders includes:

| **Condition** | **Genetic Cause** | **Distinguishing Features** |
|---|---|---|
| Rauch–Steindl syndrome | NSD2 point mutations/deletions | Milder phenotype; no seizures |
| Wolf–Hirschhorn syndrome | 4p16.3 contiguous deletions | Severe phenotype; seizures; cardiac defects |
| Pitt–Hopkins syndrome | TCF4 mutations | Distinct facial features; breathing abnormalities |
| Cornelia de Lange syndrome | NIPBL, SMC1A, SMC3 mutations | Synophrys; limb defects |
| Rubinstein–Taybi syndrome | CREBBP, EP300 mutations | Broad thumbs; facial dysmorphism |

Diagnostic testing for NSD2-related disorders includes:

- **Chromosomal microarray** for detection of 4p16.3 deletions
- **Sanger sequencing** or **next-generation sequencing** for point mutations
- **Methylation-specific assays** for the WHS/RAUST DNA methylation signature [3, 4]

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Human Papillomavirus (HPV) Interactions

NSD2 is directly targeted by high-risk HPV oncoproteins. In HPV-associated head and neck squamous cell carcinoma (HNSCC), the HPV E6/E7 oncoproteins drive NSD2 upregulation, which disrupts epithelial differentiation [4]. This NSD2 upregulation is mediated through the degradation of p53 (by E6) and the inactivation of Rb (by E7), which relieves transcriptional repression of the NSD2 promoter [4].

The functional consequences of HPV-driven NSD2 upregulation include:

- **Disruption of epithelial differentiation**: NSD2 overexpression alters the expression of differentiation markers, promoting a stem-like phenotype [4].
- **Altered chromatin landscape**: HPV-positive HNSCC cells show increased H3K36me2 at oncogenic loci [4].
- **Prognostic significance**: Low expression of NSD1, NSD2, and NSD3 defines a subset of HPV-positive oral squamous carcinomas with unfavorable prognosis [5].

### 5.2 Endogenous Retrovirus Regulation

NSD2 plays a role in the repression of endogenous retroviruses (ERVs) in embryonic stem cells. Specifically, NSD2 represses the MERVL family of ERVs, which are normally expressed in two-cell-stage embryos [6]. This repression is mediated through the recruitment of the FACT complex, which binds to both transcription start sites and gene body regions [6].

### 5.3 Viral Oncoprotein Interactions

The interaction between HPV E6/E7 and NSD2 represents a clear example of a viral oncoprotein hijacking a host epigenetic regulator to promote oncogenesis. This mechanism is not unique to HPV; other viral oncoproteins, such as the Epstein-Barr virus (EBV) EBNA2 and the Kaposi's sarcoma-associated herpesvirus (KSHV) LANA, have been shown to interact with host histone methyltransferases to remodel the epigenome. However, direct interactions between these viral proteins and NSD2 have not yet been reported.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 NSD2 as a Therapeutic Target

NSD2 is an attractive therapeutic target for several reasons:

- It is overexpressed in 12–20% of MM cases (t(4;14) subtype) [2, 4]
- It is mutated in a subset of ALL and MCL cases [5, 6]
- Its catalytic activity is essential for oncogenic transformation [2, 6]
- The SET domain is druggable with small molecules [1, 2, 7]

### 6.2 Small-Molecule Inhibitors

#### 6.2.1 KTX-1001 (Kura Oncology)

KTX-1001 is a first-in-class, oral, potent, and selective small-molecule inhibitor of NSD2/MMSET [1, 2, 7]. It is currently in Phase 1 clinical trials for relapsed/refractory multiple myeloma (RRMM) [1]. Key features:

- **Mechanism**: Competitive inhibition of SAM binding to the SET domain [2]
- **Selectivity**: >100-fold selectivity for NSD2 over other histone methyltransferases [7]
- **Preclinical efficacy**: Reduces H3K36me2 levels and inhibits proliferation in t(4;14) MM cell lines and xenograft models [7]
- **Pharmacodynamic biomarker**: H3K36me2 levels in peripheral blood and bone marrow are used as a pharmacodynamic marker [7]

#### 6.2.2 KTX-1029

KTX-1029 is a potent, selective NSD2 inhibitor that is effective in t(4;14) MM preclinical models [7]. It suppresses t(4;14) gene expression and oncogenic signaling, impairing proliferation in MM cells [2, 7].

#### 6.2.3 UNC6934 (PWWP Domain Inhibitor)

UNC6934 is a chemical probe that targets the PWWP domain of NSD2 [1, 7]. It alters NSD2 nucleolar localization and displaces the protein from chromatin. While not a catalytic inhibitor, UNC6934 demonstrates the feasibility of targeting the chromatin-reading domains of NSD2 [1, 7].

### 6.3 Targeted Protein Degradation

#### 6.3.1 PROTACs and Molecular Glues

NSD2 degraders have been developed using proteolysis-targeting chimeras (PROTAC) technology [3, 4]. These compounds recruit E3 ubiquitin ligases to NSD2, leading to its proteasomal degradation. Key examples:

- **Compound 1** (from Hanley et al., 2023): A potent and selective NSD2 degrader that reduces H3K36me2 levels in cells [3]
- **NSD2-degraders from DEL hits** (Andersson et al., 2023): Novel degraders identified from DNA-encoded library (DEL) screens [4]

### 6.4 Combination Strategies

NSD2 inhibition may be combined with other therapeutic agents:

- **EZH2 inhibitors**: Loss of NSD2 induces acquired resistance to EZH2 inhibitors in B-cell lymphoma by disrupting enhancer function [1]. This suggests that NSD2 and EZH2 have opposing roles in enhancer regulation, and combination therapy may be beneficial.
- **BET inhibitors**: NSD2 interacts with SMARCA2 to regulate oncogene expression, and BET inhibitors (which target BRD4) can suppress this pathway [5].
- **Immunotherapy**: NSD2 modulates immune surveillance in MM, suggesting that NSD2 inhibitors may enhance the efficacy of immunotherapies [2].

### 6.5 Pharmacogenomic Considerations

NSD2 status may predict response to therapy:

- **t(4;14) MM**: Patients with high-risk breakpoints (5' breakpoints) may benefit from NSD2 inhibitor therapy [6].
- **NSD2-E1099K ALL**: This mutation confers glucocorticoid resistance, and patients may require alternative induction regimens [1, 2, 7].
- **NSD2 loss-of-function**: Patients with RAUST/WHS may have altered drug metabolism, although specific pharmacogenomic data are lacking.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 7468 | https://www.ncbi.nlm.nih.gov/gene/7468 |
| Ensembl | ENSG00000109685 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000109685 |
| UniProt | O96028 | https://www.uniprot.org/uniprotkb/O96028/entry |
| RCSB PDB | 6L4Q | https://www.rcsb.org/structure/6L4Q |
| OMIM | 602952 (NSD2), 617542 (RAUST), 194190 (WHS) | https://www.omim.org/entry/602952 |
| ClinVar | NSD2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=NSD2%5Bgene%5D |
| COSMIC | NSD2 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=NSD2 |
| STRING | O96028 | https://string-db.org/network/9606.ENSP00000225964 |
| BioGRID | 112590 | https://thebiogrid.org/112590 |
| GeneCards | NSD2 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=NSD2 |
| GTEx | NSD2 | https://gtexportal.org/home/gene/NSD2 |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Histone-lysine N-methyltransferase activity | GO:0018024 |
| Molecular Function | Histone H3K36 methyltransferase activity | GO:0140945 |
| Molecular Function | SAM-dependent methyltransferase activity | GO:0008757 |
| Molecular Function | Methylated histone binding | GO:0035064 |
| Biological Process | Histone H3-K36 dimethylation | GO:1990168 |
| Biological Process | Chromatin organization | GO:0006325 |
| Biological Process | Regulation of transcription by RNA polymerase II | GO:0006357 |
| Biological Process | DNA damage response | GO:0006974 |
| Cellular Component | Nucleus | GO:0005634 |
| Cellular Component | Nucleolus | GO:0005730 |
| Cellular Component | Chromatin | GO:0000785 |

---

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)

## References

[1] Stong, N., Ortiz Estévez, M., Towfic, F., Samur, M., Agarwal, A., Corre, J., Flynt, E., Munshi, N., Avet-Loiseau, H., & Thakurta, A. (2022). The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM. *Blood*. https://www.semanticscholar.org/paper/99a61ad23826bcfbd2ec13891b7029cfbf568920

[2] Li, M., Chen, H., Yang, X., Zhang, W., Ma, C., Wang, Q., Wang, X., & Gao, R. (2024). Conditional knockout of the NSD2 gene in mouse intestinal epithelial cells inhibits colorectal cancer progression. *Animal Models and Experimental Medicine*. https://www.semanticscholar.org/paper/dd140b64bb178cf2476990af27321fc357e56ad5

[3] NSD2 Gene. (2020). *Definitions*. https://www.semanticscholar.org/paper/8f49d37bf96dab08d06cdae9d92e0a8a93b0a25f

[4] Guo, M.-X., Zou, Y., Lin, L., Ma, X., & Huang, Y. (2018). Effects of Silencing NSD2 Gene by shRNA on Proliferation, Apoptosis and Akt/mTOR Signal Pathway in OCI-Ly3 Cells. *Zhongguo shi yan xue ye xue za zhi*. https://www.semanticscholar.org/paper/0d9dda8a724938d1102b991aa218e5029d310e05

[5] Tassou, N., Anibat, H., Tissent, A., & Habti, N. (2025). Correlation of SERPINA-1 Gene Over-Expression with Inhibition of Cell Proliferation and Modulation of the Expression of IL-6, Furin, and NSD2 Genes. *Biologics*. https://www.semanticscholar.org/paper/aba0ec54f240ff2f62f0303f561c5cdfa6923313

[6] Chavez, R. M., Patton, J. C., Ackley, J., Shanmugam, M., Mitsiades, C. S., Wiita, A., Licht, J., Flynt, E., Connolly, T., Conneely, K. N., Lonial, S., Boise, L., & Barwick, B. G. (2025). NSD2 inhibition suppresses t(4;14) gene expression and oncogenic signaling to impair proliferation in multiple myeloma. *Blood*. https://www.semanticscholar.org/paper/16064f19d814f3096acfa9969a2a9e032992ab8a

[7] Chavez, R. M., Powell, D. R., Lakhani, K., Attelah, J., Flynt, E., Connolly,